{"id":"W3097505417","doi":"10.1182/blood-2020-134398","title":"The Echelon-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia; Health Sciences Centre","funders":"","keywords":"Medicine; Hazard ratio; Internal medicine; Brentuximab vedotin; CHOP; Vincristine; Prednisone; Population; Surgery; Chemotherapy regimen; Randomization; Gastroenterology; Phases of clinical research; Cyclophosphamide; Randomized controlled trial; Confidence interval; Chemotherapy; Lymphoma; CD30","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004224048,0.001869573,0.002614413,0.0003882293,0.0004024411,0.001590833,0.001136731,0.001963997,0.00443095],"category_scores_gemma":[0.002609125,0.0005672703,0.002698058,0.0003175781,0.001108226,0.001555066,0.0005937552,0.003343238,0.0008163673],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009702991,"about_ca_system_score_gemma":0.000717713,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007821524,"about_ca_topic_score_gemma":0.001554952,"domain_scores_codex":[0.9985862,0.0009267411,0.00005329699,0.0002023187,0.00008552802,0.0001460239],"domain_scores_gemma":[0.9982613,0.0005561914,0.0004686908,0.0001820482,0.00009317826,0.0004386062],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9871257,0.002002791,0.0007143437,0.0003352928,0.001260208,0.00003063068,0.00002761507,0.0002990137,0.0008226383,0.00007602344,0.0006836745,0.006622061],"study_design_scores_gemma":[0.961953,0.03294421,0.002551997,0.00004262607,0.0008917059,0.00004962624,0.00001952777,0.0004685414,0.0002428849,0.0002186316,0.0005991659,0.00001805395],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9797177,0.01020864,0.0008903164,0.001159212,0.0009060889,0.002095765,0.001976094,0.0001404906,0.002905764],"genre_scores_gemma":[0.9847798,0.002782264,0.001191826,0.002012498,0.000740835,0.002126248,0.002657766,0.00004592771,0.003662796],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00443095,"threshold_uncertainty_score":0.02233917,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02555153386881575,"score_gpt":0.2836195966986886,"score_spread":0.2580680628298729,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}